Non-reproductive consequences of polycystic ovary syndrome

Current Obstetrics and Gynaecology

Volumn 13, Issue 6, 2003, Pages 350-354

  Ledger, William L ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cancer; Diabetes; Heart disease; Metformin; Obesity; Polycystic ovary syndrome

Indexed keywords

ANTIDIABETIC AGENT; ANTIOBESITY AGENT; CLOMIFENE CITRATE; ESTROGEN; GESTAGEN; INOSITOL DERIVATIVE; METFORMIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TROGLITAZONE;

CANCER; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DIATHERMY; DRUG EFFECT; ENDOCRINE DISEASE; FEMALE; HUMAN; INSULIN RESISTANCE; LACTIC ACIDOSIS; LAPAROSCOPIC OVARIAN DIATHERMY; LAPAROSCOPIC SURGERY; LIVER TOXICITY; MENSTRUATION DISORDER; OBESITY; OVARY POLYCYSTIC DISEASE; PRACTICE GUIDELINE;

EID: 0141534198     PISSN: 09575847     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0957-5847(03)00072-6     Document Type: Conference Paper

References (12)

1. Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR. Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer 1997;79:494–499.
2. Balen AH. Polycystic ovary syndrome, cancer. Hum Reprod Update 2001;7:522–525.
3. Cheung AP. Ultrasound, menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 2001;98:325–331.
4. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992;37:119–125.
5. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand 1992;71:599–604.
6. Dunaif A, Finegood D. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab
7. Gjonnaess H. Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome. Fertil Steril 1998;69:697–701.
8. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992;36:105–111.
9. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607–613.
10. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycistic ovary syndrome at long-term follow-up. Clin Epidemiol 1998;51:581–586.
11. Velasquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647–654.
12. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-termfollow up: a retrospective cohort study. Clin Endocrinol 2000;52:595–600.